$MRK Merck &amp; Yumanity entered a collab focused on disease-modifying therapies for neurodegenerative diseases.

Merck gained exclusive rights to preclinical pipeline programs in #ALS &amp; #FTD.

Yumanity received an undisclosed u/f + up to $500M milestones. 

https://t.co/csIzaDSRUj